Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)

被引：0
|
作者：
Foody, JoAnne [1 ]
Turpin, Robin [2 ]
Tidwell, Beni [3 ]
Schulman, Kathy [4 ]
机构：
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[2] Takeda Pharmaceut Int, Med Affairs, Deerfield, IL USA
[3] ORS, Shrewsbury, MA USA
[4] Outcomes Res Solut Inc, Waltham, MA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2356
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A COMPARATIVE EVALUATION OF THE HEALTH ECONOMIC OUTCOMES OF FEBUXOSTAT AND ALLOPURINOL IN GOUT PATIENTS WITH CHRONIC KIDNEY DISEASE
    Mitri, G.
    Wittbrodt, E. T.
    Turpin, R. S.
    Costa, L. A.
    Schulman, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 445 - 445
  • [22] Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
    Helget, Lindsay
    Davis-Karim, Anne
    O'Dell, James
    Mikuls, Ted
    Newcomb, Jeff
    Androsenko, Maria
    Brophy, Mary
    England, Bryant
    Ferguson, Ryan
    Pillinger, Michael
    Neogi, Tuhina
    Wu, Hongsheng
    Palevsky, Paul
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3616 - 3618
  • [23] Pharmacologic Management of Gout in Patients with Cardiovascular Disease and Heart Failure
    Mouradjian, Mallory T.
    Plazak, Michael E.
    Gale, Stormi E.
    Noel, Zachary R.
    Watson, Kristin
    Devabhakthuni, Sandeep
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (05) : 431 - 445
  • [24] Pharmacologic Management of Gout in Patients with Cardiovascular Disease and Heart Failure
    Mallory T. Mouradjian
    Michael E. Plazak
    Stormi E. Gale
    Zachary R. Noel
    Kristin Watson
    Sandeep Devabhakthuni
    American Journal of Cardiovascular Drugs, 2020, 20 : 431 - 445
  • [25] Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
    Guan, Xudong
    Zhang, Shengzhao
    Liu, Jiayan
    Wu, Fengbo
    Zhou, Lingyan
    Liu, Ying
    Su, Na
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [26] Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease
    Terpening, Chris M. M.
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (12) : 1425 - 1435
  • [27] General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
    Saag, Kenneth
    Becker, Michael A.
    White, William B.
    Whelton, Andrew
    Borer, Jeffrey
    Gorelick, Philip
    Hunt, Barbara
    Castillo, Majin
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [28] `Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
    Hoon Jeong
    Eunmi Choi
    Ahyoung Suh
    Myungsik Yoo
    Bonggi Kim
    Rheumatology International, 2023, 43 : 265 - 281
  • [29] 'Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
    Jeong, Hoon
    Choi, Eunmi
    Suh, Ahyoung
    Yoo, Myungsik
    Kim, Bonggi
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (02) : 265 - 281
  • [30] The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?
    Katsiki, Niki
    Borghi, Claudio
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (17) : 1853 - 1856
12345